1. |
de Franchis R. Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: Report of the Baveno Ⅵ Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015, 63(3): 743-752.
|
2. |
European Association for the Study of the Liver. Electronic address: easloffice@easloffice. eu. EASL clinical practice guidelines: Vascular diseases of the liver. J Hepatol, 2016, 64(1): 179-202.
|
3. |
Kang JH, Kim DH, Kim SY, et al. Porto-sinusoidal vascular disease with portal hypertension versus liver cirrhosis: differences in imaging features on CT and hepatobiliary contrast-enhanced MRI. Abdom Radiol (NY), 2021, 46(5): 1891-1903.
|
4. |
De Gottardi A, Rautou PE, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411.
|
5. |
Lee J, Vali Y, Boursier J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int, 2021, 41(2): 261-270.
|
6. |
Dong M, Wu J, Yu X, et al. Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients. Liver Int, 2018, 38(9): 1562-1570.
|
7. |
Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. Gut, 2016, 65(8): 1369-1376.
|
8. |
WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization, 2015.
|
9. |
中华医学会传染病与寄生虫病学分会、肝病学分会. 病毒性肝炎防治方案. 中华传染病杂志, 2001, 19(1): 56-62.
|
10. |
王栋, 阴继凯, 董瑞, 等. 门静脉高压症的MDT规范化管理. 中国普外基础与临床杂志, 2022, 29(8): 981-986.
|
11. |
马军. TIPS术治疗门静脉高压症的进展与展望. 中国普外基础与临床杂志, 2022, 29(8): 997-1000.
|
12. |
Sun Y, Lan X, Shao C, et al. Clinical features of idiopathic portal hypertension in China: A retrospective study of 338 patients and literature review. J Gastroenterol Hepatol, 2019, 34(8): 1417-1423.
|
13. |
Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2 500 autopsies and a new classification of benign hepatocellular nodules. Hepatology, 1990, 11(5): 787-797.
|
14. |
Kmeid M, Liu X, Ballentine S, et al. Idiopathic non-cirrhotic portal hypertension and porto-sinusoidal vascular disease: review of current data. Gastroenterology Res, 2021, 14(2): 49-65.
|
15. |
Nicoară-Farcău O, Rusu I, Stefănescu H, et al. Diagnostic challenges in non-cirrhotic portal hypertension - porto sinusoidal vascular disease. World J Gastroenterol, 2020, 26(22): 3000-3011.
|
16. |
Schouten JN, Nevens F, Hansen B, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther, 2012, 35(12): 1424-1433.
|
17. |
Elkrief L, Rautou PE. Idiopathic non-cirrhotic portal hypertension: the tip of the obliterative portal venopathies iceberg?. Liver Int, 2016, 36(3): 325-327.
|
18. |
Barge S, Grando V, Nault JC, et al. Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies. Liver Int, 2016, 36(7): 1059-1066.
|
19. |
Riggio O, Gioia S, Pentassuglio I, et al. Idiopathic noncirrhotic portal hypertension: current perspectives. Hepat Med, 2016, 8: 81-88.
|
20. |
Goel A, Elias JE, Eapen CE, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH)—newer insights into pathogenesis and emerging newer treatment options. J Clin Exp Hepatol, 2014, 4(3): 247-256.
|
21. |
Gioia S, Nardelli S, Ridola L, et al. Causes and management of non-cirrhotic portal hypertension. Curr Gastroenterol Rep, 2020, 22(12): 56. doi: 10.1007/s11894-020-00792-0.
|
22. |
Khanna R, Sarin SK. Non-cirrhotic portal hypertension—diagnosis and management. J Hepatol, 2014, 60(2): 421-441.
|
23. |
张玉姣, 邵晨, 雷金艳, 等. 特发性非硬化性门脉高压115例临床与病理特征分析. 实用医学杂志, 2022, 38(18): 2324-2330.
|
24. |
Greil G, Geva T, Maier SE, et al. Effect of acquisition parameters on the accuracy of velocity encoded cine magnetic resonance imaging blood flow measurements. J Magn Reson Imaging, 2002, 15(1): 47-54.
|
25. |
陈丽. 肝硬化并发门静脉血栓的危险因素与预测指标相关研究分析. 重庆: 重庆医科大学, 2018.
|
26. |
Kmeid M, Zuo C, Lagana SM, et al. Interobserver study on histologic features of idiopathic non-cirrhotic portal hypertension. Diagn Pathol, 2020, 15(1): 129. doi: 10.1186/s13000-020-01049-0.
|
27. |
李玉林 , 符艳秋, 周丽诗, 等. 门-窦血管病—门静脉高压症的一种新型疾病谱. 临床肝胆病杂志, 2022, 38(12): 2850-2854.
|
28. |
Noble S, Linz M, Correia E, et al. Porto-sinusoidal vascular disease and portal hypertension. Clin Liver Dis, 2024, 28(3): 455-466.
|
29. |
Guido M, Alves VAF, Balabaud C, et al. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition. Histopathology, 2019, 74(2): 219-226.
|
30. |
Guido M, Sarcognato S, Sacchi D, et al. Pathology of idiopathic non-cirrhotic portal hypertension. Virchows Arch, 2018, 473(1): 23-31.
|